BioMarin to Participate in Two Upcoming Virtual Investor Conferences

On February 16, 2022 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that management will participate in two upcoming virtual conferences (Press release, BioMarin, FEB 16, 2022, View Source [SID1234608183]). An audio webcast of the presentations will be available live. You can access the webcast at: View Source An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE

On February 16, 2022 Amgen (NASDAQ:AMGN) reported that it has been named to Newsweek magazine’s list of "America’s Most Responsible Companies" for the third consecutive year; JUST Capital’s list of "America’s Most JUST Companies" for the fifth consecutive year; Barron’s list of "America’s Most Sustainable Companies" for the second consecutive year; and the Human Rights Campaign Foundation’s list of "Best Places to Work for LGBTQ+ Equality" for the sixth consecutive year (Press release, Amgen, FEB 16, 2022, View Source [SID1234608182]). These rankings reflect the company’s enduring commitment to environmental, social, and governance (ESG) issues.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Amgen’s mission is to serve patients and our ESG programs enable us to achieve that mission responsibly," said Judy Brown, senior vice president, Corporate Affairs at Amgen. "We will continue to do our part to build a better, healthier world by addressing the challenges facing society that matter most to our business and to our stakeholders."

Amgen’s four ESG pillars – Healthy People, Healthy Society, Healthy Planet, and a Healthy Amgen – include commitments to:

Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed.1
Improve the diversity of its workforce as well as the diversity of patients participating in clinical trials of potential new Amgen medicines.
Provide employees with enhanced mental health support, including programs focused on communities of color, as well on the pandemic-related challenges facing parents.
Double its spend with diverse suppliers in the U.S. and triple its spend with Black-owned businesses by 2023.
Inspire the next generation of innovators through science education programs sponsored by the Amgen Foundation2 that reached over 24 million students worldwide last year.
Help those who are unable to afford the medicines they need through the Amgen Safety Net Foundation3, which has provided approximately $6 billion4 of our medicines at no cost over the past five years to qualifying patients in the United States.

Carl H. June to be Keynote Speaker at 2021 Summit4CI!

On February 16, 2022 BioCanRx reported Dr. Carl H. June as our distinguished keynote speaker for the 2022 Summit for Cancer Immunotherapy (Summit4CI) taking place November 19-21, 2022 (Press release, BioCanRx, FEB 16, 2022, View Source;utm_medium=rss&utm_campaign=carl-h-june-keynote-speaker-2021-summit4ci-2 [SID1234608181]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. June is the Richard W. Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania. The impact of his work has become widely recognized as a major turning point that is delivering on the long-held promise of cancer gene therapy. Dr. June is a pioneer in immunotherapy research who spearheaded the development of chimeric antigen receptor (CAR) T-cell therapy, a new tool for treating cancer that involves extracting a patient’s immune cells and genetically engineering them so they can attack and kill their cancer. This treatment received FDA approval in August 2017, followed by more approvals for varying countries and indications. Dr. June has published over 350 manuscripts and has received multiple awards and honours.

Summit4CI 2022 is taking place in Montréal, Quebec, at the Fairmont the Queen Elizabeth. Please join us Saturday, November 19 to Monday, November 21 as we explore the latest progress in cancer immunotherapy from scientific, clinical, industry and patient perspectives during BioCanRx’s sixth scientific conference. In addition to our feature keynote speaker Dr. June, this year’s Summit4CI will feature internationally recognized speakers, networking and social events, an HQP Development Day, scientific presentations, poster sessions, a public forum, an Oxford-style debate, and more. We hope to see you at the conference! Learn more here.

PERRIGO ANNOUNCES QUARTERLY DIVIDEND

On February 16, 2022 Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, reported that its Board of Directors approved a 7% increase in the Company’s quarterly dividend to $0.26 per share, or $1.04 per share on an annual basis, from $0.24 per share (Press release, Perrigo Company, FEB 16, 2022, View Source [SID1234608180]). This dividend increase marks the 19th consecutive year Perrigo has increased its dividend.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The cash dividend is payable on March 17, 2022 to shareholders of record on February 28, 2022.

Genmab Publishes 2021 Annual Report

On February 16, 2022 Genmab A/S (Nasdaq: GMAB) reported the publication of its Annual Report for 2021 (Press release, Genmab, FEB 16, 2022, View Source [SID1234608179]). Below is a summary of business progress in 2021, financial performance for the year and the financial outlook for 2022 . The full report is attached as a PDF file and can be found in the investor section of the company’s website, www.genmab.com/investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call
Genmab will hold a conference call in English to discuss the full year results for 2021 today, February 16, 2022 at 6:00 pm CET, 5:00 pm GMT or noon EST. To join the call dial +1 631 913 1422 (U.S. participants) or +44 3333 000804 (international participants) and provide conference code 76485840.

A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investors.

2021 ACHIEVEMENTS

Business Progress
Bring our own medicines to patients

Tisotumab vedotin1 — U.S. FDA decision on BLA and progress to market — achieved
Tisotumab vedotin — Japanese New Drug Application (JNDA) submission in cervical cancer — potential JNDA filing timeline postponed to include Phase 3 innovaTV 301 data
Epcoritamab2 — acceleration & maximization of development program by advancing expansion cohorts and initiating additional Phase 3 trials — partial criteria was met for this goal in 2021, further progress is anticipated in 2022

Build world-class differentiated product pipeline

DuoBody-PD-L1x4-1BB3 — expansion cohort data — achieved
DuoBody-CD40x4-1BB3 — dose escalation data — achieved
Tisotumab vedotin — data in other tumor indication — achieved
Earlier stage products — progress & expand innovative product pipeline — partial criteria was met for this goal in 2021, further progress is anticipated in 2022
Become leading integrated innovation powerhouse

Operational commercialization model in US & Japan — achieved
Further strengthen solid financial foundation — achieved
Financial Performance

Net sales of DARZALEX by Janssen Biotech Inc. (Janssen) were USD 6,023 million in 2021 compared to USD 4,190 million in 2020, an increase of USD 1,833 million, or 44%.
Royalty revenue was DKK 6,977 million in 2021 compared to DKK 4,741 million in 2020, an increase of DKK 2,236 million, or 47%. The increase was driven by higher net sales of DARZALEX, TEPEZZA and Kesimpta resulting in higher royalties.
Total revenue was DKK 8,482 million in 2021. In addition to the royalty revenue described above, Genmab also recognized DKK 954 million of milestone revenue during 2021. Revenue in 2020 was DKK 10,111 million and included the one-time upfront payment of DKK 4,398 million recognized as license revenue from AbbVie Inc. (AbbVie) pursuant to our collaboration announced in June 2020.
Operating expenses were DKK 5,464 million in 2021 compared to DKK 3,798 million in 2020. The increase of DKK 1,666 million, or 44%, was driven by the continued advancement of multiple pipeline projects, the increase in new team members to support the launch of Tivdak and expansion of our product pipeline, as well as the continued development of commercialization capabilities and Genmab’s broader organizational infrastructure.
Operating profit was DKK 3,018 million in 2021 compared to DKK 6,313 million in 2020. The decrease of DKK 3,295 million, or 52%, was driven by lower revenue as a result of the non-recurring license revenue in 2020 associated with the upfront payment from AbbVie and increased operating expenses.

Revenue
Genmab expects its 2022 revenue to be in the range of DKK 10,800 – 12,000 million, compared to DKK 8,482 million in 2021. Our revenue in 2021 was driven primarily by the continued strong growth of DARZALEX net sales.

Genmab’s projected revenue for 2022 primarily consists of DARZALEX royalties of DKK 7,700 – 8,500 million. Such royalties are based on estimated DARZALEX 2022 net sales of USD 7.3 – 8.0 billion compared to actual net sales in 2021 of approximately USD 6.0 billion. Since the second quarter of 2020, Janssen has reduced its royalty payments to Genmab by what it claims to be Genmab’s share of Janssen’s royalty payments to Halozyme Therapeutics, Inc. in connection with subcutaneous sales. Given the ongoing arbitration, Genmab has reflected this as a reduction to estimated 2022 revenue. The remainder of Genmab’s revenue consists of increasing royalties from TEPEZZA, Kesimpta and RYBREVANT, reimbursement revenue, milestones for epcoritamab, other milestones and collaboration revenue related to Tivdak commercialization efforts in the U.S. as part of our Seagen Inc. (Seagen) collaboration.

Operating Expenses
Genmab anticipates its 2022 operating expenses to be in the range of DKK 7,200 – 7,800 million, compared to DKK 5,464 million in 2021. The increase is driven by the advancement of Genmab’s clinical programs, continued investment in research and development, as well as building Genmab’s commercial organization and broader organizational infrastructure.

Operating Profit
We expect our operating profit to be in the range of DKK 3,000 – 4,800 million in 2022, compared to DKK 3,018 million in 2021.

More information on the Risks and Assumptions for the 2022 Financial Guidance can be found in the 2021 Annual Report available on our website www.genmab.com/investors.